(1) 药效关联的癌症单细胞亚群识别与精准联合医疗研究，国家自然科学基金面上项目，主持，在研。

(2) 药物对动植物细胞作用机制研究，横向项目，主持，在研。

(3) 非小细胞肺癌不同KRAS突变型的治疗异质性与精准联合用药研究，国家自然科学基金面上项目，主持，结题。

(4) 基于高通量药物基因组学数据的肺癌个性化联合用药方案筛选和评估，国家自然科学基金面上项目，主持，结题。

(5) 头颈部恶性肿瘤个性化药物评价及临床转化体系建立，精准医学研究重点专项，参与，结题。

(6) 运用比较基因组学基于基因关系传递模式研究基因表达调控的进化机制，国家自然科学基金青年项目，主持，结题。

(7) miRNA在心脏和血管发育过程中的调控作用，973重大专项，参与，结题。

1. Zheng J, Chen S, Zhang Y, Zhang B,Qiao K, Xu J, Fan Y, Feng M, Feng Z, Wang Z, Wang H*. PMADS: anintegrated database of curated and proteomics-inferred associations betweenprotein posttranslational modifications and drug sensitivity. Nucleic Acids Res. 2025 Oct 16:gkaf1033. Epub ahead of print.

2. Liu P#, Zheng J#,Ma W#, Lü J, Zhao Q, Li D, Jiang X, Wang H, Wang H*, Yu Z*. StressPromotes Lung Metastasis in Breast Cancer by Altering Neutrophil Differentiation.  Cancer Res. 2025 Sep 24. Epub ahead of print.

3. Tian P#, Zheng J#,Qiao K, Fan Y, Xu Y, Wu T, Chen S, Zhang Y, Zhang B, Ambrogio C, Wang H*.scPharm: Identifying Pharmacological Subpopulations of Single Cells forPrecision Medicine in Cancers. Adv Sci (Weinh). 2024 Nov 19:e2412419.

4. Wu T#, Dai Y#, Xu Y, Zheng J, ChenS, Zhang Y, TianP, Zheng X*, WangH*. ExosomePurity: tumourpurity deconvolution in serum exosomes based onmiRNA signatures. Briefings inBioinformatics. 2023 May 19;24(3):bbad119.

5. Chen S#,Zheng J#, Zhang B, TangX, Cun Y, Wu T, XuY, Ma T, Cheng J, Yu Z*,WangH*. Identification and characterization ofvirus-encoded circular RNAs inhost cells. Microb Genom.2022Jun;8(6):mgen000848.

6. Huang X, Xu Y, Qian L, Zhao Q, Liu P, Lü J, GuoY,Ma W, Wang G, Li S, Luo A, Yang X, Wang H*,Yu Z*. Evolution of geneexpressionsignature in mammary gland stem cells from neonatal to old mice. Cell Death Dis. 2022 Apr 12;13(4):335.

7. Xu Y, Zheng J, Cai Z, Li W, Köhler J, Dai Y,ChengX, Wu T, Zhang F, WangH*. TherapeuticResponse-Based Reclassification of Multiple Tumor SubtypesReveals IntrinsicMolecular Concordance of Therapy Across HistologicallyDisparate Cancers. Front Cell Dev Biol.2021 Nov 12;9:773101.

8. Zheng J, Wang H*. Pharmaco-omics data sheds light ontherapy-orientedprospects of precision medicine. EBioMedicine.2021 Aug;70:103493(Commentary).

9. Dai Y, Cao Y, Köhler J, Lu A, Xu S*, Wang H*.UnbiasedRNA-Seq-driven identification and validation of reference genes forquantitativeRT-PCR analyses of pooled cancer exosomes. BMCGenomics. 2021 Jan6;22(1):27.

10. Cai Z#, Xue H#,Xu Y, Köhler J, Cheng X, Dai Y,Zheng J, WangH*.Fcirc: Acomprehensive pipeline for the exploration of fusion linear andcircular RNAs. GigaScience.2020Jun 1;9(6):giaa054.

11. Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C,Varela C, Gómez-LópezG, Fernández-García F, Sanclemente M, Guerra C, Drosten M,Galán J, Caleiras E,Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D,Musteanu M*, Barbacid M*. Tumor regression andresistance mechanisms upon CDK4and RAF1 inactivation in KRAS/P53 mutant lungadenocarcinomas. Proc Natl Acad Sci U S A. 2020 Sep29;117(39):24415-24426.

12. Luo A#, Xu Y#,Li S#, Bao J, Lü J, DingN, Zhao Q,Fu Y, Liu F, Cho WC, Wei X*, WangH*, Yu Z*. Cancer stem cell property and gene signature inbone-metastaticBreast Cancer cells. Int J Biol Sci.2020 Jul19;16(14):2580-2594.

13. WangH*, Lv Q, Xu Y, Cai Z, Zheng J,Cheng X, Dai Y, Jänne P, Ambrogio C*, KöhlerJ*. An integrativepharmacogenomics analysis identifies therapeutic targets inKRAS-mutant lungcancer. EbioMedicine.2019 Nov;49:106-117.

14. Chen W, Wang J,Shi J, Yang X, Yang P, Wang N, YangS, XieT, Yang H, Zhang M, WangH*, Fei J*. Longevity Effect of Liuwei Dihuang in Both CaenorhabditisElegans andAged Mice. Aging and Disease.2019 Jun 1;10(3):578-591.

15. Liu R#,Wang J#, Ukai M, Sewon K,Chen P, Suzuki Y, Wang H*, AiharaK*, Okada-Hatakeyama M*, Chen L*. Hunt for the tipping point duringendocrineresistance process in breast cancer by dynamic network biomarkers. J Mol Cell Biol. 2018 Nov 1. 

16. Ambrogio C*, Köhler J, Zhou ZW, Wang H, Paranal R,Li J, Capelletti M, Caffarra C, Li S, Lv Q,Gondi S, Hunter JC, Lu J, Chiarle R,Santamaría D, Westover KD*, Jänne PA*. KRAS Dimerization Impacts MEKInhibitorSensitivity and Oncogenic Activity of Mutant KRAS. Cell.2018 Feb 8;172(4):857-868.e15.

17. Liu Y, Fei T, Zheng X, Brown M, Zhang P*, Liu X*, Wang H*. Anintegrative pharmacogenomic approach identifiestwo-drug combination therapiesfor personalized cancer medicine. SciRep. 2016, 26:6.

18. Zhang N#, Wang H#,Fang Y, Wang J*, Zheng X*, LiuX*.Predicting anticancer drug responses using a dual-layer integratedcellline-drug network model. PlosComputational Biology. 2015 Sep29;11(9).

19. WangH*#,Zheng X#, Fei T, Wang J, Li X, LiuY, Zhang F. Towards pathway-centric cancertherapies via pharmacogenomicprofiling analysis of ERK signalling pathway. Clin Transl Med. 2015Dec;4(1):66.

20. Wang J#,Zhang Y#, Wang H#, Dong N, Bao L, SunX, Xu M, Wang X*.Global analyses of subtype- or stage-specific genes onchromosome 7 in patientswith lung cancer. Cancer Metast Rev.2015 Jun;34(2).

21. WangH*,Meyer C, Fei T, Wang G, Zhang F*, Liu X. A systematic approachidentifies FOXA1as a key factor in the loss of epithelial traits duringtheepithelial-to-mesenchymal transition in lung cancer. BMC Genomics. 2013, 14:680.

22. WangH*,Wang Q, Shen B and Li X*.Systematic investigation of global coordination amongmRNA and protein incellular society. BMCGenomics. 2010, 11:364

23. WangH*#,Wang Q*#,Li X, Shen B, Ding M and Shen Z. Towards patterns tree of genecoexpression ineukaryotic species. Bioinformatics.2008,24(11)：1367-1373.